How is cutaneous Squamous Cell Carcinoma (cSCC) treated?
If your skin lesions are left untreated, they may continue to grow, which can cause damage to surrounding tissue. The cancer can even spread to other parts of your body and in rare cases, can lead to death.
There are several treatment options for cSCC. Which treatment option is best for you depends on the size, location and aggressiveness of the tumour. Treatment options may include:
Superficial Treatments
cSCC is usually treated with surgery. However, early stage cSCC is often treated effectively through superficial treatments that treat the top layer of the skin. Treatments for early stage (cSCC in situ, Bowen’s disease or stage T or 0) may include topical chemotherapy creams or gels, cryotherapy, or photodynamic therapy (PDT).
The treatment option that is best for you will depend on the size, location and aggressiveness of the tumour. If your skin lesions are left untreated, they may continue to grow, which can cause damage to surrounding tissue. The cancer can even spread to other parts of your body and in rare cases, can lead to death.
Topical Treatments
Photodynamic Therapy (PDT)
Systemic Drug Therapy
Systemic drug therapy is currently used only in advanced or metastatic cases for squamous cell carcinoma. Systemic therapies are drugs that spread throughout the body to treat cancer cells wherever they may be. They have many different forms such as chemotherapy, targeted drugs, and immunotherapy.
Chemotherapy:
Chemotherapy has been used to treat cSCC, but there has been no standard chemotherapy treatment plan for non-melanoma skin cancer.[1]
Immunotherapy
Immunotherapies are a new class of drugs that have been developed to stimulate a person’s own immune system to recognize and destroy cancer cells. Immunotherapies act to release the brakes of the immune system, allowing it to mount a stronger and more effective attack against cancer cells. These drugs are usually given in hospital or specialized clinic by intravenous.
Recently, the immunotherapy cemiplimab (Libtayo) was approved in Canada for the treatment of adult patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or curative radiation.[3]
Learn more about cemiplimab (Libtayo)
WATCH NOW – CSCC WEBINAR
Cutaneous Squamous Cell Carcinoma – Updates in Immunotherapy presented by Dr. Butler MD